Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 19/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21900141 | 0.92 | GLS (0.62) | GLSKCNH2 | |
| SCHEMBL22193574 | 0.83 | GLS (0.89) | GLSKCNH2SLC6A2TACR1OPRM1 | |
| SCHEMBL21900338 | 0.82 | GLS (0.64) | GLSKCNH2SLC6A2TACR1OPRM1 | |
| SCHEMBL22193563 | 0.80 | GLS (0.75) | GLSKCNH2SLC6A2TACR1OPRM1 | |
| SCHEMBL21900361 | 0.80 | GLS (0.70) | GLSKCNH2SLC6A2TACR1OPRM1 | |
| SCHEMBL21900349 | 0.80 | GLS (0.58) | GLSKCNH2 | |
| SCHEMBL24109070 | 0.79 | GLS (0.45) | GLSKCNH2 | |
| SCHEMBL21900811 | 0.79 | GLS (0.56) | GLSKCNH2SLC6A2TACR1OPRM1 | |
| SCHEMBL24108984 | 0.78 | GLS (0.60) | GLSKCNH2SLC6A2TACR1OPRM1 | |
| SCHEMBL22193575 | 0.78 | GLS (0.72) | GLSKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254666-B2 | Compound as GLS1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| EP-3640250-B1 | COMPOUND AS GLS1 INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-20200216436-A1 | COMPOUND AS GLS1 INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2020-07-09 | — | — | US | disclosed |
| EP-3640250-A1 | COMPOUND AS GLS1 INHIBITOR | Medshine Discovery Inc. (CN) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254666-B2 | Compound as GLS1 inhibitor | GLS, GLS2, GLB1 | GLS 1/4885KCNH2 701/4885SLC6A2 312/4885 |
| US-20200216436-A1 | COMPOUND AS GLS1 INHIBITOR | GLS, GLS2, GLB1 | GLS 1/4885KCNH2 701/4885SLC6A2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.